These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27620474)

  • 1. Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin.
    Ong V; Hough G; Schlosser M; Bartizal K; Balkovec JM; James KD; Krishnan BR
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6872-6879. PubMed ID: 27620474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.
    Hall D; Bonifas R; Stapert L; Thwaites M; Shinabarger DL; Pillar CM
    Diagn Microbiol Infect Dis; 2017 Nov; 89(3):205-211. PubMed ID: 28826987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties.
    James KD; Laudeman CP; Malkar NB; Krishnan R; Polowy K
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
    Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
    J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species.
    Locke JB; Almaguer AL; Zuill DE; Bartizal K
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6100-7. PubMed ID: 27480852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species.
    Ong V; James KD; Smith S; Krishnan BR
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.
    Damle BD; Dowell JA; Walsky RL; Weber GL; Stogniew M; Inskeep PB
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1149-56. PubMed ID: 19029327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD101: a novel long-acting echinocandin.
    Zhao Y; Perez WB; Jiménez-Ortigosa C; Hough G; Locke JB; Ong V; Bartizal K; Perlin DS
    Cell Microbiol; 2016 Sep; 18(9):1308-16. PubMed ID: 27354115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.
    Kuti EL; Kuti JL
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1287-300. PubMed ID: 20822479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Potential of anidulafungin in hematological patients].
    Vázquez López L; Ruiz Camps I
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():44-50. PubMed ID: 19572434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.
    Lepak AJ; Zhao M; VanScoy B; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis.
    Boikov DA; Locke JB; James KD; Bartizal K; Sobel JD
    J Antimicrob Chemother; 2017 May; 72(5):1355-1358. PubMed ID: 28158577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Int J Antimicrob Agents; 2017 Sep; 50(3):352-358. PubMed ID: 28689871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
    Estes KE; Penzak SR; Calis KA; Walsh TJ
    Pharmacotherapy; 2009 Jan; 29(1):17-30. PubMed ID: 19113794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anidulafungin: a novel echinocandin for candida infections.
    de la Torre P; Meyer DK; Reboli AC
    Future Microbiol; 2008 Dec; 3(6):593-601. PubMed ID: 19072176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anidulafungin--state of affairs from a clinical perspective.
    Vehreschild JJ; Kümmerle T; Karthaus M; Cornely OA
    Mycoses; 2007; 50 Suppl 1():38-43. PubMed ID: 17394608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility.
    Krishnan BR; James KD; Polowy K; Bryant BJ; Vaidya A; Smith S; Laudeman CP
    J Antibiot (Tokyo); 2017 Feb; 70(2):130-135. PubMed ID: 27507631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anidulafungin: when and how? The clinician's view.
    George J; Reboli AC
    Mycoses; 2012 Jan; 55(1):36-44. PubMed ID: 21668526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.